Evaluation of a Phosphate Management Protocol to Achieve Optimum Serum Phosphate Levels in Hemodialysis Patients

Journal of Renal Nutrition

Volumn 18, Issue 6, 2008, Pages 521-529

  Yokum, Dawn ^a   Glass, Georgina ^a   Cheung, Ching Fun ^b   Cunningham, John ^c   Fan, Stanley ^a   Madden, Angela M ^d  

^a BARTS HEALTH NHS TRUST   (United Kingdom)

^b BEDFORD HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING PROTEIN; VITAMIN D;

ARTICLE; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATIENT EDUCATION; PATIENT PARTICIPATION; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

CALCIUM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROID HORMONE; PATIENT EDUCATION AS TOPIC; PATIENT PARTICIPATION; PHOSPHATE-BINDING PROTEINS; PHOSPHATES; RENAL DIALYSIS; TREATMENT OUTCOME; VITAMIN D;

EID: 53749085211     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2008.05.003     Document Type: Article

References (32)

1. Fan S.L.S., and Cunningham J. How should hyperphosphataemia be managed in dialysis patients?. Semin Dial 15 (2002) 321-324
2. Raggi P. Imaging of cardiovascular calcifications with electron beam tomography in haemodialysis patients. Am J Kidney Dis 37 Suppl 2 (2001) S62-S65
3. Norris K.C. Towards a new treatment paradigm for hyperphosphataemia in chronic renal disease. Dial Transplant 27 (1998) 767-772
4. Pohlmeier R., and Vienken J. Phosphate removal and hemodialysis conditions. Kidney Int 78 Suppl (2001) S190-S194
5. Slatopolsky E., Brown A., and Dusso A. Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 37 Suppl 2 (2001) S54-S57
6. Stamatakis M.K., Pecora P.G., and Gunel E. Factors influencing adherence in chronic dialysis patients with hyperphosphataemia. J Ren Nutr 7 (1997) 144-148
7. Prowant B.F., Ryan L.P., Satalowich R.J., et al. Effectiveness of a phosphorous educational program for dialysis patients. ANNA J 16 (1998) 353-357
8. Schlatter S., and Ferrans C.E. Teaching program effects on high phosphorus levels in patients receiving haemodialysis. ANNA J 25 (1998) 31-35
9. Ashurst I.B., and Dobbie H. A randomised controlled trial of an educational intervention to improve phosphate levels in haemodialysis patients. J Ren Nutr 13 (2003) 267-274
10. Hecking E., Bragg-Gresham J.L., Rayner H.C., et al. Haemodialysis prescription, adherence and nutritional indicators in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 19 (2004) 100-107
11. Department of Health: Patient group directions. Health service circular 2000/026. Available at: http://www.dh.gov.uk/PublicationsAndStatistics/LettersAndCirculars/HealthServiceCirculars/HealthServiceCircularsArticle/fs/en?CONTENT_ID=4004179&chk=Kncufs. Accessed April 8, 2006
12. Bingham S.A. The dietary assessment of individuals: methods, accuracy, new techniques and recommendations. Nutr Abstr Rev 57 (1987) 705-742
13. Smith A.F., Beckett G.J., Walker S.W., et al. Lecture notes on clinical biochemistry. 6th ed. (1998), Blackwell Science, Oxford
14. Thomas L. Calcium. In: Thomas L. (Ed). Clinical laboratory diagnostics: use and assessment of clinical laboratory results (1998), TH-Books Verlagsgesellschaft, Frankfurt-am-Main 231-241
15. Godber I.M., Parker C.R., Lawson N., et al. Comparison of intact and "whole molecule" parathyroid hormone assays in patients with histologically confirmed post-renal transplant osteodystrophy. Ann Clin Biochem 39 (2002) 314-317
16. Roberts N.B., Clough A., Bellia J.P., et al. Increased absorption of aluminium from a normal dietary intake in dementia. J Inorgan Biochem 69 (1998) 171-176
17. Daugirdas J.T. Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol 4 (1993) 1205-1213
18. National Kidney Foundation. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 Suppl 3 (2003) S1-S201
19. Cupisti A., D'Alessandra C., Baldi R., et al. Dietary habits and counselling focused on phosphate intake in hemodialysis patients with hyperphosphatemia. J Ren Nutr 14 (2004) 220-225
20. Ford J.C., Pope J.F., Hunt A.E., et al. The effect of diet education on the laboratory values and knowledge of hemodialysis patients with hyperphosphatemia. J Ren Nutr 14 (2004) 36-44
21. Ritzerfeld M., Klasser M., and Mann H. Alfacalcidol in the therapy of renal bone disease. Int J Clin Pharmacol Ther 39 (2001) 546-550
22. McIntyre C.W., Patel V., Taylor G.S., et al. A prospective study of combination therapy for hyperphosphataemia with calcium-containing phosphate binders and sevelamer in hypercalcaemic haemodialysis patients. Nephrol Dial Transplant 17 (2002) 1643-1648
23. Craven C., and Moreschi J. A dietitian-driven protocol for the management of renal bone disease in hemodialysis patients. J Ren Nutr 6 (1996) 105-109
24. Ruffino M., de Bonis E., Martin M., et al. Is it possible to control hyperphosphataemia with diet without inducing protein malnutrition?. Nephrol Dial Transplant 13 Suppl 3 (1998) 65-67
25. Pifer T.B., McCullough K.P., Port F.K., et al. Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS. Kidney Int 62 (2002) 2238-2245
26. Braun J., Asmus H.G., Holzer H., et al. Long-term comparison of a calcium-free phosphate binder and calcium carbonate-phosphate metabolism and cardiovascular calcification. Clin Nephrol 62 (2004) 104-115
27. Block G.A., Spiegel D.M., Ehrlich J., et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68 (2005) 1815-1824
28. Alfrey A.C., Legendre G.R., and Kaehny W.D. The dialysis encephalopathy syndrome: possible aluminum intoxication. N Engl J Med 294 (1976) 184-188
29. Pierides A.M., Edwards W.G., Cullum U.X., et al. Hemodialysis encephalopathy with osteomalacia fractures and muscle weakness. Kidney Int 18 (1980) 115-125
30. Slatopolsky E.A., Burke S.K., Dillon M.A., et al. RenaGel, a nonabsorbed calcium- and aluminium-free phosphate binder, lowers serum phosphate and parathyroid hormone. Kidney Int 55 (1999) 299-307
31. Sturtevant J.M., Hawley C.M., Reiger K., et al. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders. Nephrology (Carlton) 9 (2004) 406-413
32. Coladonato J.A. Control of hyperphosphatemia among patients with ESRD. J Am Soc Nephrol 16 Suppl (2005) S107-S114